We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




BBI Solutions to Showcase Technologies for Next-Generation Diagnostics

By LabMedica International staff writers
Posted on 15 Nov 2017
Print article
Image: BBI Solutions will showcase its Morffi signal enhancement technology at MEDICA 2017, the world’s largest medical trade fair (Photo courtesy of BBI Solutions).
Image: BBI Solutions will showcase its Morffi signal enhancement technology at MEDICA 2017, the world’s largest medical trade fair (Photo courtesy of BBI Solutions).
Immunoassay development and manufacturing specialist BBI Solutions (Cardiff, UK) will showcase its award-winning Morffi signal enhancement technology at the world’s largest medical trade fair, MEDICA 2017, which runs from November 13 to 16 in Dusseldorf, Germany. The Morffi signal enhancement technology is a patent pending conjugate blocking technology that could provide a two-fold enhancement in the limit of detection in both plasma and urine as compared to existing gold conjugation methods; enabling lateral flow immunoassays to compete with traditional lab-based testing platforms.

Additionally, BBI Solutions, along with its sister company, BBI Group’s mobile arm, Novarum (Scotland, UK), will showcase their innovative mobile technology which allows users to read and share results of lateral flow diagnostic tests using just a smartphone. The company’s smartphone readers enable tests to be accurately read from the point of care, at a patient’s home or in remote and challenging environments, with the results shared securely with healthcare professionals or specific end-users.

“This is an incredibly exciting period of growth and innovation for the business. We’re looking forward to the opportunity to outline BBI Solutions’ enhanced capabilities and showcase the potential presented by our landmark Morffi technology,” said Liam Taylor, managing director of BBI Solutions. “The combined impact of BBI Solutions’ and Novarum’s technology offers an outstanding end-to-end solution that has the potential to revolutionize the lateral flow diagnostics landscape and we relish the chance to showcase this compelling proposition during the event.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.